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Introduction
Autosomal dominant hypocalcemia (ADH) is a disorder of  systemic calcium homeostasis caused by 
increased sensitivity of  the calcium-sensing receptor (CaSR) signaling pathway to extracellular calcium 
(Ca2+o) concentrations (1, 2). The CaSR is a widely expressed class C G-protein coupled receptor (GPCR) 
that plays a pivotal role in Ca2+o homeostasis by transducing elevations in the prevailing Ca
2+
o concentra-
tion into multiple signaling cascades that include Gq/11-protein–mediated activation of  phospholipase C 
(PLC), which in the parathyroid glands induce increases in intracellular calcium (Ca2+i) and MAPK sig-
naling responses that lead to decreased parathyroid hormone (PTH) secretion (3). ADH is associated with 
hypocalcemia, hyperphosphatemia, hypomagnesemia, and inappropriately low or normal PTH concentra-
tions; some patients may also be hypercalciuric (1, 4) or develop a Bartter-like syndrome characterized by 
hypokalemic alkalosis, renal salt wasting, and hyperreninemic hyperaldosteronism (5, 6). Approximately 
50% of  patients develop symptomatic hypocalcemia, and >35% have ectopic calcifications within the kid-
neys and basal ganglia (1, 2, 7, 8). ADH is a genetically heterogeneous disorder comprised of  two variants, 
which are known as ADH type 1 (ADH1) and ADH type 2 (ADH2). ADH1 (OMIM #601198) is caused 
by germline mutations of  the CaSR, which is encoded by the CASR gene on chromosome 3q21.1 (1, 9), 
whereas, ADH2 (OMIM #615361) is caused by germline mutations of  the widely expressed G-protein 
Heterozygous germline gain-of-function mutations of G-protein subunit α11 (Gα11), a signaling 
partner for the calcium-sensing receptor (CaSR), result in autosomal dominant hypocalcemia 
type 2 (ADH2). ADH2 may cause symptomatic hypocalcemia with low circulating parathyroid 
hormone (PTH) concentrations. Effective therapies for ADH2 are currently not available, and a 
mouse model for ADH2 would help in assessment of potential therapies. We hypothesized that 
a previously reported dark skin mouse mutant (Dsk7) — which has a germline hypermorphic Gα11 
mutation, Ile62Val — may be a model for ADH2 and allow evaluation of calcilytics, which are CaSR 
negative allosteric modulators, as a targeted therapy for this disorder. Mutant Dsk7/+ and Dsk7/
Dsk7 mice were shown to have hypocalcemia and reduced plasma PTH concentrations, similar 
to ADH2 patients. In vitro studies showed the mutant Val62 Gα11 to upregulate CaSR-mediated 
intracellular calcium and MAPK signaling, consistent with a gain of function. Treatment with NPS-
2143, a calcilytic compound, normalized these signaling responses. In vivo, NPS-2143 induced a 
rapid and marked rise in plasma PTH and calcium concentrations in Dsk7/Dsk7 and Dsk7/+ mice, 
which became normocalcemic. Thus, these studies have established Dsk7 mice, which harbor a 
germline gain-of-function Gα11 mutation, as a model for ADH2 and have demonstrated calcilytics as 
a potential targeted therapy.
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subunit α 11 (Gα 11) protein, which is encoded by the GNA11 gene on chromosome 19p13.3 (2, 7, 8, 10). Both 
CaSR and Gα 11 mutations identified in ADH patients have been demonstrated to enhance CaSR-mediated 
Ca2+i and MAPK signaling in cellular studies, consistent with a gain of  function (1, 2, 7, 9–11).
Mouse models with gain-of-function Casr mutations have been generated by chemical mutagenesis and 
knock-in strategies, and they have been shown to have a phenotype closely resembling ADH1 in humans 
with hypocalcemia, hyperphosphatemia, reduced PTH concentrations, hypercalciuria, and ectopic cal-
cifications (12, 13). Such models have been utilized to evaluate calcilytic compounds, which are nega-
tive allosteric CaSR modulators that represent a potential targeted therapy for ADH (14–17). Indeed, a 
long-acting amino-alcohol calcilytic compound known as NPS-2143 has been shown in vivo to rectify 
the hypocalcemia of  Nuf mice, which harbor a germline gain-of-function Casr mutation, Leu723Gln (13, 
18). Recent in vitro studies have also revealed NPS-2143 to normalize the gain of  function caused by Gα11 
mutations that lead to ADH2 (11). However, it remains unclear whether this calcilytic may rectify the 
hypocalcemia associated with ADH2, and mouse models that harbor Gna11 mutations in association with 
hypocalcemia have not been reported to be available for such in vivo studies. Such mouse models would 
also aid the further phenotypic characterization of  ADH2, as limited information is available from the 
small numbers of  patients studied to date (2, 7, 8, 10, 19).
To develop a mouse model for ADH2, we conducted studies to investigate the calcitropic phenotype of  
a previously reported mouse mutant known as Gna11Mhdadsk7 or “dark skin 7”, and henceforth referred to as 
Dsk7, which has increased dermal pigmentation in association with a germline hypermorphic Gna11 muta-
tion, Ile62Val (formerly referred to as Ile63Val) (20). We hypothesized that Dsk7 mice would exhibit dysreg-
ulation of  Ca2+o homeostasis in keeping with ADH2. Our study has revealed Dsk7 mice to have hypocalce-
mia and reduced PTH concentrations, which are caused by a gain-of-function Gna11 mutation that leads 
to upregulation of  CaSR-mediated Ca2+i and MAPK signaling responses. Moreover, we demonstrate that 
NPS-2143 treatment rectifies this gain of  function in vitro and ameliorates the hypocalcemia of  Dsk7 mice.
Results
Genotype and phenotype studies of  Dsk7 mice. DNA sequence analysis of  Gna11 in Dsk7 mice confirmed the 
reported A-to-G transition (c.184A>G, RefSeq Accession NM_002067.4) at codon 62 of  the Gα11 protein, 
resulting in an Ile to Val missense substitution (Supplemental Figure 1, A and B; supplemental material 
available online with this article; https://doi.org/10.1172/jci.insight.91103DS1) (20). This mutation also 
led to the loss of  a FokI restriction endonuclease site (Supplemental Figure 1B), as reported (20), which 
was used to confirm the presence of  the mutation in Dsk7 mice (Supplemental Figure 1, C and D) and for 
genotyping of  subsequent generations. Analysis of  offspring bred from crosses of  Dsk7/+ × Dsk7/+ mice 
showed that the proportion bred as homozygous-affected Dsk7/Dsk7 mice were >30% less (x2 = 10.20, 
degrees of  freedom [df] = 2, P < 0.01) than would be expected from a Mendelian pattern of  inheritance 
(Supplemental Table 1). The Dsk7/Dsk7 mice also had significantly reduced body weight and increased 
skin pigmentation (data not shown), when compared with age-matched WT (+/+) mice (Table 1), as 
previously reported (20).
Biochemical analysis of  plasma samples collected under isoflurane terminal anesthesia revealed male 
and female Dsk7/+ and Dsk7/Dsk7 mice to be significantly hypocalcemic and hyperphosphatemic, and to 
have significantly reduced PTH concentrations when compared with +/+ mice (Figure 1 and Table 1). 
The hypocalcemia was significantly more marked in Dsk7/Dsk7 mice compared with heterozygous-affect-
ed Dsk7/+ mice (Figure 1 and Table 1). Reduced FGF-23 concentrations were noted in Dsk7/Dsk7 mice 
compared with +/+ mice (Table 1). No significant differences were observed in plasma urea and creat-
inine concentrations, alkaline phosphatase activity, or 1,25-dihydroxyvitamin D concentrations (Table 
1). Twenty-four–hour urinary calcium excretion and urinary calcium/creatinine ratios were significantly 
reduced in female Dsk/+ mice, although fractional excretion of  calcium was not different between either 
male or female Dsk7 mice and respective +/+ mice (Table 2). The tubular maximum reabsorption of  
phosphate (TmP) was significantly increased in Dsk7/+ and Dsk7/Dsk7 mice (Table 2), consistent with 
the low circulating PTH concentrations of  these mice (Figure 1 and Table 1) (21). Fractional excretion of  
sodium and potassium were not altered (Table 2). Whole body dual-energy X-ray absorptiometry (DXA) 
showed no differences in bone mineral density (BMD) between male and female Dsk7 mice and respective 
+/+ mice (Table 3). μCT analysis of  trabecular bone also showed no alterations in the bone volume frac-
tion or in the thickness or number of  trabeculae between male or female Dsk7 mice and respective +/+ 
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mice (Table 3). Ophthalmological 
examination did not reveal any lens 
opacifications in Dsk7/Dsk7 mice 
(data not shown), and these findings 
contrast with Nuf  mice, which har-
bor a gain-of-function Casr mutation 
in association with hypocalcemia 
and cataracts (18).
Effects of  Ile62Val Gα11 mutation 
on Gα11 structure and CaSR-mediat-
ed signaling. The Ile62 residue is 
located within the α1 helix of  the 
GTPase domain of  Gα11 and close 
to the Arg60 residue, which has been 
reported to be mutated in ADH2 
patients (Figure 2A) (7, 8). The WT 
Ile62 residue, which is encoded in 
exon 2 of  the Gna11 gene (Figure 
2A), is absolutely conserved in Gα11 
orthologs and highly conserved in 
Gα-subunit paralogs (Figure 2B). To 
determine the importance of  the WT 
Ile62 residue for Gα11 function, homology modeling was undertaken using the crystal structure of  the relat-
ed Gαq and Gα i proteins (22, 23). This revealed the WT Ile62 residue to be located at the interface between 
the Gα-subunit helical and GTPase domains (Figure 2C) and to comprise part of  a conserved hydrophobic 
cluster of  amino acid residues within the GTPase domain of  the Gα-subunit, which play a key role in stabi-
lizing G-proteins in an inactive GDP-bound conformation (Figure 2D) (23). These findings predicted that 
mutation of  the conserved WT Ile62 Gα11 residue to a mutant Val62 residue would destabilize the inactive 
GDP-bound Gα-subunit, thereby leading to guanine-nucleotide exchange and Gα11 activation (23).
To determine the effects of  these predicted changes in Gα11 structure on CaSR-mediated signaling, 
HEK293 cells stably expressing the CaSR (HEK-CaSR) were transiently transfected with pBI-CMV2-
GNA11 constructs expressing either the WT (Ile62) or mutant (Val62) Gα11 proteins. This bidirectional 
pBI-CMV2 vector allows for coexpression of  Gα11 and GFP at equivalent levels (2); expression of  the 
CaSR, Gα11, and GFP was confirmed by fluorescence microscopy and/or Western blot analyses (Figure 
3, A and B). The expression of  Gα11 was shown to be similar in cells transiently transfected with WT or 
mutant proteins and shown to be greater than that observed in untransfected cells (Supplemental Figure 
2). The expression of  mutant Gα11 in transfected cells, together with that of  the endogenous expression of  
WT Gα11, corresponds to the heterozygous situation in vivo (Figure 3B and Supplemental Figure 2). The 
responses of  Ca2+i to alterations in [Ca
2+]o of  cells expressing the different GNA11 vectors were assessed 
by flow cytometry. The Ca2+i responses in WT and mutant Gα11-expressing cells were shown to increase 
in a dose-dependent manner following stimulation with increasing concentrations of  Ca2+o. However, 
responses in mutant Val62-expressing cells were significantly elevated compared with WT-expressing cells 
Figure 1. Calcitropic phenotype of Dsk7 
mice. (A and B) Plasma adjusted-calci-
um, (C and D) plasma phosphate, and 
(E and F) plasma PTH concentrations 
of male and female WT (+/+, circles), 
Dsk7/+ (squares), and Dsk7/Dsk7 (tri-
angles) mice, respectively. Mean ± SEM 
values for the respective groups are indi-
cated by the solid bars. *P < 0.05, **P < 
0·01, ***P < 0.001. A Kruskal-Wallis test 
followed by Dunn’s test for nonparamet-
ric pairwise multiple comparisons were 
used for analysis of A–F.
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(Figure 3C). Thus, the Val62 mutant–expressing cells showed a leftward shift in the concentration-re-
sponse curve (Figure 3C), with significantly reduced mean half-maximal response (EC50) value (P < 0.001, 
n = 7) of  2.57 mM (95% CI, 2.47–2.67 mM) for Val62-expressing cells, compared with 3.02 mM (95% 
CI, 2.93–3.10 mM) for WT-expressing cells (Figure 3D), consistent with a gain of  function of  the Gα11 
mutant, as observed with Gα11 mutations that lead to ADH2 (2, 7, 10, 11). The Val62 Gα11 mutant did not 
alter the maximal Ca2+i signaling responses (Figure 3E) but was associated with a significant reduction of  
the Hill coefficient (P < 0.01) (Figure 3F).
In vitro effects of  NPS-2143 treatment on Ca2+i and MAPK responses of  the Val62 Gα11 mutant. To investigate 
whether allosteric inhibition of  the CaSR can rectify the gain of  function associated with the Ile62Val Gα11 
mutation, NPS-2143 was added at 20 and 40 nM concentrations, as similar doses of  this calcilytic have been 
reported to rectify the altered signaling responses associated with ADH2-causing Gα11 mutations (11). An 
Table 1. Age, weight and plasma biochemical profile of WT and Dsk7 mice
Male Female
+/+ Dsk7/+ Dsk7/Dsk7 +/+ Dsk7/+ Dsk7/Dsk7
Age (weeks) 13.6 ± 0.2 (n = 27) 13.5 ± 0.2 (n = 29) 13.5 ± 0.3 (n = 17) 13.7 ± 0.3 (n = 24) 13.7 ± 0.2 (n = 31) 13.7 ± 0.2 (n = 20)
Weight (g) 32.2 ± 0.4 (n = 11) 33.9 ± 0.6 (n = 12) 28.9 ± 0.9B (n = 10) 30.8 ± 0.4 (n = 11) 29.4 ± 1.1 (n = 12) 24.6 ± 0.9D (n = 7)
Plasma biochemistry
Sodium (mmol/L) 151 ± 0.4 (n = 12) 151 ± 0.9 (n = 13) 150 ± 0.2 (n = 9) 148 ± 1.1 (n = 11) 146 ± 1.3 (n = 12) 150 ± 1.2 (n = 7)
Potassium (mmol/L) 5.5 ± 0.1 (n = 13) 5.2 ± 0.1 (n = 12) 5.0 ± 0.1 (n = 10) 4.5 ± 0.2 (n = 11) 4.9 ± 0.3 (n = 11) 4.5 ± 0.2 (n = 7)
Urea (mmol/L) 12.6 ± 0.4 (n = 12) 11.5 ± 0.4 (n = 13) 12.9 ± 0.2 (n = 9) 9.1 ± 0.6 (n = 11) 8.7 ± 0.8 (n = 12) 10.9 ± 1.0 (n = 7)
Creatinine (μmol/L) 11.9 ± 0.5 (n = 13) 12.1 ± 0.8 (n = 12) 12.8 ± 0.5 (n = 10) 11.6 ± 0.6 (n = 11) 11.8 ± 0.5 (n = 12) 12.9 ± 1.3 (n = 7)
Calcium (mmol/L)A 2.51 ± 0.02 (n = 25) 2.20 ± 0.01B (n = 
25)
1.98 ± 0.05B (n = 15) 2.45+0.03 (n = 22) 2.19 ± 0.02B (n = 29) 1.90 ± 0.03B (n = 17)
Magnesium(mmol/L) 0.86 ± 0.02 (n = 11) 0.82 ± 0.02 (n = 14) 0.87 ± 0.02 (n = 6) 0.87 ± 0.02 (n = 10) 0.83 ± 0.01 (n = 17) 0.78 ± 0.02 (n = 10)
Phosphate (mmol/L) 2.23 ± 0.1 (n = 20) 3.01 ± 0.07C (n = 22)3.96 ± 0.24B (n = 13) 2.43 ± 0.07 (n = 13) 2.89 ± 0.1D (n = 19) 3.19 ± 0.19C (n = 15)
ALP (U/L) 93.2 ± 2.3 (n = 12) 95.3 ± 2.8 (n = 13) 93.3 ± 5.2 (n = 10) 120 ± 8.4 (n = 11) 127 ± 4.9 (n = 12) 121 ± 8.5 (n = 7)
PTH (ng/L) 404 ± 44 (n = 12) 133 ± 13C (n = 12) 64 ± 19B (n = 6) 283 ± 41 (n = 11) 158 ± 21D (n = 16) 50 ± 9B (n = 12)
1,25D (pmol/L) 109 ± 15 (n = 14) 86 ± 11 (n = 13) 59 ± 11 (n = 5) 85 ± 9 (n = 13) 58 ± 6 (n = 16) 60 ± 12 (n = 12)
FGF-23 (ng/L) 270 ± 45 (n = 10) 174 ± 23 (n = 13) 120 ± 29E (n = 6) 200 ± 39 (n = 11) 110 ± 14 (n = 18) 74 ± 13D (n = 8)
APlasma calcium concentrations were adjusted for the plasma albumin concentration. ALP, alkaline phosphatase activity; PTH, parathyroid 
hormone; 1,25D, 1,25 dihydroxyvitamin D; FGF-23, fibroblast growth factor-23. All values are expressed as mean ± SEM. BP < 0.001, CP < 0.01, DP 
< 0.05, EP = 0.05, compared with respective WT (+/+) mice. A Kruskal-Wallis test followed by Dunn’s test for nonparametric pairwise multiple 
comparisons were used for all analyses.
 
Table 2. Urine biochemical profile of WT and Dsk7 mice
Male Female
+/+ Dsk7/+ Dsk7/Dsk7 +/+ Dsk7/+ Dsk7/Dsk7
24hr Ca 2.14 ± 0.28 (n = 13) 1.99 ± 0.23 (n = 13) 2.0 ± 0.23 (n = 10) 2.71 ± 0.24 (n = 11) 1.70 ± 0.20A (n = 12) 1.78 ± 0.32 (n = 7)
Ca/Cr 0.22 ± 0.01 (n = 12) 0.22 ± 0.02 (n = 13) 0.23 ± 0.03 (n = 10) 0.29 ± 0.03 (n = 11) 0.19 ± 0.01A (n = 12) 0.23 ± 0.03 (n = 7)
FECa 0.001 ± 0.0001 (n 
= 12)
0.001 ± 0.0001 (n 
= 12)
0.001 ± 0.0002 (n 
= 9)
0.001 ± 0.0001 (n 
= 11)
0.001 ± 0.0003 (n 
= 12)
0.002 ± 0.0002 (n 
= 7)
FENa 0.004 ± 0.0002 (n 
= 13)
0.004 ± 0.0001 (n 
= 12)
0.004 ± 0.0002 (n 
= 10)
0.003 ± 0.0002 (n 
= 11)
0.004 ± 0.0002 (n 
= 12)
0.004 ± 0.0004 (n 
= 7)
FEK 0.14 ± 0.006 (n = 13) 0.14 ± 0.007 (n = 12) 0.18 ± 0.02 (n = 10) 0.12 ± 0.007 (n = 11) 0.14 ± 0.007 (n = 11) 0.14 ± 0.009 (n = 7)
TmP/GFR 2.4 ± 0.2 (n = 13) 3.0 ± 0.1A (n = 13) 4.3 ± 0.2C (n = 10) 2.4 ± 0.1 (n = 11) 3.1 ± 0.1B (n = 12) 3.7 ± 0.2C (n = 7)
Parameters were measured using urine samples obtained over a 24-hour period. Urinary calcium excretion values are shown as μmol/24 hours. Calcium/creatinine 
ratios (Ca/Cr) are shown as mmol/mmol. FECa, fractional excretion of calcium; FENa, fractional excretion of sodium; FEK, fractional excretion of potassium; TmP/
GFR, ratio of tubular maximum reabsorption of phosphate (TmP) to GFR. All values are expressed as mean ± SEM. AP < 0.05, BP < 0.01, CP < 0.001 compared with 
respective WT (+/+) mice. A Kruskal-Wallis test followed by Dunn’s test for nonparametric pairwise multiple comparisons were used for all analyses.
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assessment of  Ca2+i responses showed 20 nM NPS-2143 to increase the EC50 of  Val62-expressing mutant 
cells to 2.97 mM (95% CI, 2.88–3.08 mM), so that this was not significantly different from the EC50 of  
untreated WT cells (Figure 3, C and D). However, addition of  NPS-2143 at the higher 40 nM dose increased 
the EC50 of  mutant cells to a value of  3.48 mM (95% CI, 3.42–3.55 mM), which was significantly greater 
than that of  untreated WT cells (P < 0.001) (Figure 3, C and D). NPS-2143 had no effect on the maximal 
responses or Hill coefficients of  mutant-expressing cells (Figure 3, E and F).
Some gain-of-function Gα11 mutations have been reported to promote tumorigenesis by constitutively 
upregulating MAPK signaling (24), and we therefore assessed the oncogenic potential of  the Ile62Val Gα11 
mutation in HEK-CaSR cells by measurements of  phosphorylated ERK (pERK), which is a key component 
of  the MAPK cascade (7, 25). WT and mutant pBI-CMV2-GNA11 vectors were transiently transfected into 
HEK-CaSR cells, and the fold-change increases in pERK proteins were measured following exposure to 
varying [Ca2+] o . Western blot analysis confirmed expression of  WT and mutant Gα11 proteins in cells used 
for the pERK experiments (Figure 4A). In the absence of  Ca2+o stimulation, the basal pERK responses of  the 
Val62 mutant were not significantly different from cells expressing WT Gα11 (Figure 4B), whereas exposure 
to Ca2+o led to significantly increased pERK fold-change responses of  cells expressing the Val62 Gα11 mutant 
(Val62 = 9.4 ± 1.4) when compared with cells expressing WT Gα11 (Ile62 = 4.1 ± 0.5, P < 0.01) (Figure 4B). 
Figure 2. Structural characterization of the Ile62Val Gα11 mutation. (A) Genomic organization of Gna11 showing location of the Ile62Val mutation. The Gα11 
GTPase domain (encoded by exon 1, 5′portion of exon 2, 3′ portion of exon 4 and exons 5–7) is connected to the helical domain (encoded by the 3′ portion of 
exon 2, exon 3, and 5′ portion of exon 4) by the linker 1 (L1) and 2 (L2) peptides. The Ile62Val mutation (red) lies within the α1 helix (green). The location of 
reported ADH2 mutations are indicated (black). (B) Multiple protein sequence alignment of residues comprising the α1 helix and L1 peptide of Gα11-subunit 
orthologs (top) and Gα-subunit paralogs (bottom). Conserved residues are shown in gray. The WT (Ile) and Dsk7 mutant (m) (Val) residues are shown in 
red. (C) Homology model of the Gα11 protein. The Gα helical (blue) and GTPase (green) domains are connected by the L1 and L2 peptides (gray). GDP (black) 
is bound at the interdomain interface. Previously reported residues mutated in ADH2 are shown in yellow. The mutated Ile62 residue is shown in red. (D) 
Close-up view of the Ile62 residue, which lies within a hydrophobic cluster of residues (blue spheres) on α1, α5, and β1 of the GTPase domain and near to 
the interdomain interface (dotted line) and GDP binding site.
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NPS-2143 was next added to cells expressing the Val62 Gα11 mutant protein (Figure 4C) and which had 
been stimulated with 10 mM Ca2+o. Exposure to 20 nM of  this calcilytic compound normalized the elevated 
pERK responses (Figure 4D). The effect of  the Val62 Gα11 mutant on MAPK signaling was also investigated 
by measuring gene transcription induced by a serum-response element (SRE) containing luciferase report-
er construct, which is a downstream mediator of  ERK signaling (7, 25). Western blot analysis confirmed 
expression of  WT and mutant Gα11 proteins in cells used for the SRE reporter experiments (Figure 4E). In 
Figure 3. Intracellular calcium responses of the Val62 Gα11 mutant and effect of NPS-2143 treatment. (A) Fluorescence 
microscopy of HEK293 cells stably expressing CaSR (HEK-CaSR) and transiently transfected with WT Ile62 or mutant (m) 
Val62 pBI-CMV2-GNA11 constructs. GFP expression in these cells indicates successful transfection and expression by these 
constructs. Scale bars: 10 μm. (B) Western blot analysis of lysates from HEK-CaSR cells used for flow cytometry experi-
ments. Transient transfection with WT or mutant Val62 expression constructs resulted in overexpression of Gα11 and GFP. 
Calnexin, a housekeeping protein, and untransfected cells (Supplemental Figure 2) were used as controls. (C) Ca2+i response 
to changes in [Ca2+]o of HEK-CaSR cells transfected with WT or Val62 Gα11 mutant. The Ca
2+
i responses to changes in [Ca
2+]o 
are expressed as a percentage of the maximum normalized responses and shown as the mean ± SEM of 5–8 assays from 2 
independent transfections. The Val62 Gα11 mutant led to a leftward shift in the concentration-response curve (red line). The 
addition of 20 nM NPS-2143 rectified the leftward shift of the Val62 Gα11 mutant (red dashed line), whereas 40 nM NPS-2143 
led to a rightward shift of the mutant concentration-response curve (pink dashed line) compared with WT (black line). (D–F) 
Histograms showing mean ± SEM EC50 values, % maximal signaling responses, and Hill coefficients, respectively, for cells 
expressing WT (open bar) or Val62 Gα11 mutant (black bar) proteins and for mutant-expressing cells treated with NPS-2143 
(patterned bars). **P < 0.01, ***P <0.001. F-test for C–D. Mann-Whitney U test for E–F.
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the absence of  Ca2+o stimulation, the basal SRE reporter activity of  the Val62 mutant was not significantly 
different from cells expressing WT Gα11 (Figure 4F), whereas Ca
2+
o stimulation led to significantly increased 
SRE reporter fold-change responses of  cells expressing the Val62 Gα11 mutant (Val62 = 20.7 ± 1.5 compared 
with 11.0 ± 0.4 for the Ile62 WT Gα11, P < 0.01) (Figure 4F). NPS-2143 was then added at a dose of  20 
nM to cells expressing the Val62 Gα11 mutant protein (Figure 4G), in the presence of  10 mM Ca
2+
o, and this 
normalized the increased SRE reporter responses (Figure 4H).
In vivo effects of  NPS-2143 on the hypocalcemia of  Dsk7 mice. We next assessed whether the hypocalcemia 
of  Dsk7 mice may be improved by treatment with NPS-2143. Previous studies have demonstrated that i.p. 
administration of  a 30 mg/kg NPS-2143 dose significantly increases plasma calcium and PTH concentra-
tions in Nuf mice with a gain-of-function Casr mutation, but it is associated with adverse effects on renal 
function (13). In contrast, a study using oral gavage administration of  NPS-2143 in WT rats has reported 
that a dose of  100 μmol/kg can increase PTH responses without adverse renal effects (26). We therefore 
evaluated the effects of  i.p. and oral gavage administration of  NPS-2143 in +/+ mice, and we showed 
that a single oral gavage 100 μmol/kg dose of  NPS-2143 significantly increased plasma calcium without 
altering renal function, whereas i.p. injection of  this calcilytic led to a significant rise in plasma urea and 
creatinine (Supplemental Figure 3). We therefore administered a 100 μmol/kg bolus of  NPS-2143 by oral 
gavage to +/+, Dsk7/+, and Dsk7/Dsk7 mice and measured PTH, calcium, phosphate, urea, and creatinine 
concentrations at 0, 1, 2, 6, and 24 hours after dose using plasma samples obtained from the lateral tail 
vein following application of  topical local anesthesia. Administration of  NPS-2143 led to a 4- to 5-fold 
elevation in plasma PTH concentrations in +/+, Dsk7/+, and Dsk7/Dsk7 mice, with a maximal rise in 
PTH occurring at 1–2 hours after dose (Figure 5, A–C). The rise in PTH was associated with a significant 
increase in plasma calcium concentrations in +/+, Dsk7/+, and Dsk7/Dsk7 mice, which were maximally 
elevated (0.25–0.5 mmol/l above baseline values) at 2 hours after dose (Figure 5, D–F). Indeed, admin-
istration of  100 μmol/kg NPS-2143 normalized the plasma calcium concentrations of  Dsk7/Dsk7 mice, 
whereas Dsk7/+ mice became transiently hypercalcemic (Figure 5, D–F). NPS-2143 treatment also led to a 
transient rise in plasma phosphate concentrations in +/+ and Dsk7/Dsk7 mice (Figure 5, G–I), which was 
not associated with any increases in plasma urea or creatinine (Supplemental Figure 4). Thus, these studies 
demonstrate that a single dose of  NPS-2143 can rectify the hypocalcemia of  Dsk7/+ and Dsk7/Dsk7 mice.
Discussion
Our studies have demonstrated that Dsk7 mice, which harbor a germline Ile62Val Gna11 mutation (20), 
are hypocalcemic, are hyperphosphatemic, and have reduced circulating PTH concentrations. Thus, 
Table 3. Bone parameters of WT and Dsk7 mice
Male Female
+/+ Dsk7/+ Dsk7/Dsk7 +/+ Dsk7/+ Dsk7/Dsk7
Whole body DXA
BMD 
(g/cm2)
0.064 ± 0.001 
(n = 6)
0.063 ± 0.002 
(n = 6)
0.061 ± 0.001 
(n = 4)
0.062 ± 0.002 
(n = 10)
0.065 ± 0.002 
(n = 10)
0.058 ± 0.003 
(n = 5)
Proximal tibia μCT
BV 
(mm3)
0.78 ± 0.04 
(n = 6)
0.71 ± 0.04 
(n = 6)
0.65 ± 0.03 
(n = 6)
1.13 ± 0.08 
(n = 6)
1.11 ± 0.08 
(n = 6)
1.10 ± 0.06 
(n = 6)
BV/TV 
(%)
27 ± 1.7 
(n = 6)
27 ± 1.0 
(n = 6)
29 ± 2.1 
(n = 6)
50 ± 3.7 
(n = 6)
52 ± 2.3 
(n = 6)
60 ± 1.0 
(n = 6)
Tb. Th 
(mm)
0.10 ± 0.001 
(n = 6)
0.98 ± 0.002 
(n = 6)
0.10 ± 0.003 
(n = 6)
0.14 ± 0.005 
(n = 6)
0.15 ± 0.005 
(n = 6)
0.16 ± 0.006 
(n = 6)
Tb. N 
(mm-1)
2.7 ± 0.1 
(n = 6)
2.7 ± 0.1 
(n = 6)
2.8 ± 0.1 
(n = 6)
3.5 ± 0.1 
(n = 6)
3.5 ± 0.1 
(n = 6)
3.6 ± 0.1 
(n = 6)
SMI 1.9 ± 0.2 
(n = 6)
1.7 ± 0.1 
(n = 6)
1.8 ± 0.1 
(n = 6)
0.7 ± 0.2 
(n = 6)
0.5 ± 0.2 
(n = 6)
–0.1 ± 0.2 
(n = 6)
DXA, dual-energy X-ray absorptiometry; BMD, bone mineral density; BV, bone volume; BV/TV, cancellous bone volume fraction as a proportion of total 
possible organ (tissue) volume; Tb. Th, trabecular thickness; Tb. N, trabecular number; SMI, structural model index. All values are expressed as mean ± 
SEM. A Kruskal-Wallis test followed by Dunn’s test for nonparametric pairwise multiple comparisons were used for all analyses.
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Dsk7 mice represent a mouse model for the human disorder of  ADH2, which is caused by gain-of-func-
tion GNA11 mutations (2, 7, 8, 10). In support of  this, the Ile62Val Gα11 mutant protein enhanced the 
signaling responses of  CaSR-expressing cells in vitro, and this data indicates that the Gna11 mutation 
is leading to the observed phenotype in Dsk7 mice. The Ile62Val Gna11 mutation showed a gene dosage 
effect with the heterozygous-affected Dsk7/+ mice having an ~0.3 mmol/l decrease in plasma calcium 
and ~65% reduction in PTH concentrations compared with +/+ mice, whereas homozygous-affected 
Dsk7/Dsk7 mice have significantly more pronounced hypocalcemia (plasma calcium ~0.5 mmol/l lower 
Figure 4. MAPK responses of the Val62 Gα11 mutant and effect of NPS-2143 treatment. (A) Western blot analysis of lysates from HEK-CaSR cells used 
for phosphorylated ERK (pERK) experiments. (B) pERK fold-change responses to changes in [Ca2+]o of cells transfected with WT (solid line) or Val62 Gα11 
mutant (dashed line). (C) Western blot analysis of lysates from cells used to assess effect of NPS-2143 (2143) on pERK responses. (D) Effect of NPS-2143 
on pERK responses of Val62 Gα11 mutant. (E) Western blot analysis of lysates from HEK-CaSR cells used for serum response element (SRE) reporter experi-
ments. (F) SRE reporter fold-change responses to changes in [Ca2+]o of cells transfected with WT (solid line) or Val62 Gα11 mutant (dashed line). (G) Western 
blot analysis of lysates from cells used to assess effect of NPS-2143 on SRE reporter responses. (H) Effect of NPS-2143 on the SRE reporter responses 
of the Val62 Gα11 mutant. The Val62 Gα11 mutant led to significantly increased pERK and SRE fold-change responses following stimulation with Ca
2+
o. In 
the absence of Ca2+o, the pERK and SRE responses of the Val62 Gα11 mutant were not significantly different from WT, thereby indicating the Ile62Val Gα11 
mutation to be nonconstitutively activating. The addition of 20 nM NPS-2143 decreased the pERK and SRE responses of cells expressing the Val62 Gα11 
mutant (patterned bars) compared with untreated cells (solid bars), so that these were not significantly different from WT (open bars). The fold-change 
responses are shown as the mean ± SEM of 4–8 independent transfections. *P < 0.05, **P < 0.01. Mann-Whitney U test for B, D, F, and H.
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than +/+ mice) and a greater (~85%) reduction in PTH concentrations (Figure 1 and Table 1). The 
more severe hypocalcemia of  homozygous-affected mice may potentially have affected their viability, 
thereby providing an explanation for the observed reduced numbers of  mice with this genotype. The 
degree of  hypocalcemia of  affected Dsk7 mice is similar to that of  ADH2 patients, who have been 
reported to have serum calcium values ranging between 0.1–0.6 mmol/l below that of  unaffected family 
members (7, 8, 27). Moreover, Dsk7 mice generally had detectable circulating PTH concentrations and 
also a normal fractional excretion of  calcium, which is in keeping with the majority of  ADH2 patients 
(2, 7, 8). The markedly reduced circulating PTH of  Dsk7/Dsk7 mice was not significantly associat-
ed with decreases in plasma 1,25-dihydroxyvitamin D concentrations (Table 1), and such effects of  
PTH may have been counteracted by the low plasma FGF-23 concentrations, which would be expected 
to increase 1,25-dihydroxyvitamin D (28). Serum FGF-23 concentrations have not been reported for 
ADH2 patients, and our finding of  low FGF-23 values in Dsk7/Dsk7 mice was most likely a conse-
quence of  the hypocalcemia, which has been previously shown to reduce circulating FGF-23 concen-
trations in parathyroidectomized rats and in rats with hypocalcemia due to dietary calcium restriction 
(29). However, the mechanism by which hypocalcemia lowers FGF-23 remains to be established (29). 
The bone phenotype of  ADH2 has been evaluated in a single kindred by plain radiography, and no 
abnormalities were identified (19). Our skeletal assessment of  Dsk7 mice also did not reveal any major 
alterations in BMD or trabecular volume or structure, which indicates that gain-of  function Gα11 muta-
tions may not lead to alterations in bone metabolism.
Figure 5. Effect of NPS-2143 on plasma PTH, calcium, and phosphate of Dsk7 mice at 0, 1, 2, 6, and 24 hours after dose. (A–C) Plasma PTH, (D–F) plasma 
adjusted-calcium, and (G–I) plasma phosphate concentrations of WT (+/+), Dsk7/+, and Dsk7/Dsk7 mice, respectively. Mean values for the respective 
groups are indicated by solid bars. n = 4–7 mice per study time point. Squares, males; circles, females. *P < 0.05, **P < 0.01. A Kruskal-Wallis test followed 
by Dunn’s test for nonparametric pairwise multiple comparisons were used for analysis of A–I.
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In addition to Dsk7 mice having similar calcitropic features to ADH2 patients, Dsk7 mice may also 
share some noncalcitropic phenotypes with affected patients. Indeed, short stature has been reported in 2 
ADH2 kindreds (7, 19), and in keeping with this, Dsk7/Dsk7 mice have been previously noted to have sig-
nificantly reduced body length and weight compared with +/+ mice (20). However, a key species-specific 
difference is that Dsk7/+ and Dsk7/Dsk7 mice have increased skin pigmentation, due to an expansion of  the 
melanocyte population within the dermis (30), and such alterations in skin color have not been reported 
for ADH2 patients to date. The studies of  Dsk7 mice and ADH2 patients have also revealed differences to 
the phenotype of  ADH1, which is caused by gain-of-function CASR mutations (1, 9). In particular, ADH1 
patients and knock-in mice harboring ADH1-causing Casr mutations have been demonstrated to have a rela-
tive or absolute hypercalciuria and high bone mass (1, 12), in addition to hypocalcemia and low circulating 
PTH concentrations. These alterations in parathyroid, renal, and bone metabolism observed in ADH1 are 
in keeping with the known expression and function of  the CaSR in these tissues (31–33). In contrast, our 
finding that Dsk7 mice have hypocalcemia and low PTH values in the absence of  renal or bone abnormalities 
suggests that germline Gα11 mutations may influence CaSR signaling responses in the parathyroid gland 
without perturbing the function of  this GPCR in other calcitropic tissues (Figure 1 and Tables 1–3). In 
support of  this, studies of  mice with a parathyroid-specific ablation of  the Gαq/11 proteins (34) have demon-
strated a critical role for these proteins in PTH secretion, whereas it remains to be established if  these G-pro-
teins act as a signaling partner for the CaSR in the kidneys and bone. Moreover, the lack of  a renal or bone 
phenotype in Dsk7 mice may also have been caused by alterations in the relative expression of  Gα11 and Gαq. 
Thus, if  Gαq expression predominates in kidney and bone, then a gain of  function of  Gα11 may have been 
insufficient to alter CaSR signaling responses in these tissues. An additional difference in the phenotypes 
associated with gain-of-function mutations of  the CaSR and Gα11 proteins is that Nuf  mice — which have 
hypocalcemia in association with a germline Casr mutation, Leu723Gln — developed cataracts by 4–6 weeks 
of  age (18), whereas Dsk7 mice do not have lens abnormalities. The CaSR has been reported to be expressed 
and functionally linked to Ca2+-activated K+ channels in lens epithelial cells (35); however, its role in cataract 
formation has not been determined. The absence of  lens opacifications in Dsk7 mice indicates that alter-
ations in CaSR-mediated Gα11 signaling may not be involved in the development of  this eye disorder.
Our findings help to elucidate some of  the mechanisms whereby the germline Ile62Val Gα11 mutation, 
which involves the substitution of  amino acid residues with similar hydrophobic properties, causes a gain 
of  function and enhances the sensitivity of  CaSR-expressing cells to Ca2+o. The WT Gα11 Ile62 residue 
appears to be absolutely conserved among multicellular organisms and is located within the Gα-subunit α1 
helix at the interdomain interface, which contains a hydrophobic cluster of  residues involved in guanine 
nucleotide binding (Figure 2) (23). Upon binding of  G-protein to GPCR, the α1 helix has been shown to 
undergo conformational changes that destabilize the interdomain interface, thereby leading to the exchange 
of  GDP for GTP (23), which triggers G-protein activation. It is likely that the Ile62Val mutation leads to 
a gain of  function by decreasing the stability of  the α1 helix, and this possibility is supported by reported 
mutagenesis studies involving the related Gαi protein, which have shown substitution of  the homologous 
Gαi Ile residue with alanine to destabilize the GDP-bound form of  the Gα-subunit (23). The Gα11 interdo-
main interface and hydrophobic residue cluster represent a hotspot for gain-of-function mutations, with 5 
out of  6 of  the reported ADH2-causing mutations situated within this region (2, 7, 8, 10), consistent with 
our proposal that these mutations likely alter the conformation of  the guanine nucleotide-binding pocket, 
thereby promoting GDP-GTP exchange and G-protein activation.
Although the Val62 Gα11 mutant protein enhanced the Ca
2+
i responses of  CaSR-expressing cells, consis-
tent with a gain of  function, it also significantly reduced the Hill coefficient, which was not rectifiable with 
calcilytic treatment (Figure 3). The Hill coefficient is commonly used to represent cooperative receptor-li-
gand interactions (36) but may also indicate the degree of  interaction between a GPCR and its downstream 
partner signaling protein (25). Our finding of  a reduced Hill coefficient suggests that the Ile62Val mutation 
may have altered coupling of  the mutant Gα11 protein with the CaSR. In support of  this, ADH1-causing 
mutations located within the CaSR transmembrane domain, which is predicted to be the site of  G-protein 
binding, have also been reported to lower the Hill coefficient, while leading to a gain of  function (37).
The most severe clinical manifestation of  GNA11 mutations is uveal melanoma, which is a malignant 
tumor arising from the melanocytes of  the choroid plexus, ciliary body, and iris and which is caused by 
somatic mutations of  the Arg183 and Qln209 Gα11 residues that lead to constitutive upregulation of  MAPK 
signaling (24). As the Ile62Val Gna11 mutation is associated with increased proliferation of  melanocyte 
Downloaded from http://insight.jci.org on February 15, 2018.   https://doi.org/10.1172/jci.insight.91103
1 1insight.jci.org   https://doi.org/10.1172/jci.insight.91103
R E S E A R C H  A R T I C L E
precursors in Dsk7 mice (20), we assessed the oncogenic potential of  this mutation in vitro and demon-
strated that it increased MAPK responses only in the presence of  Ca2+o stimulation (Figure 4). Thus, the 
Ile62Val Gα11 mutant does not harbor constitutive activity, and these findings are consistent with previously 
reported ADH2 mutations, which also lead to a nonconstitutive gain of  function (7, 11) and are supported 
by studies of  double mouse mutants, which have shown that the Ile62Val Gna11 mutation does not cause 
increased skin pigmentation in the absence of  an upstream functional receptor (20).
ADH2 is frequently associated with hypocalcemic symptoms such as paraesthesia, muscle cramps, 
carpo-pedal spasm, and seizures (2, 7, 8, 10). However, treatment of  symptomatic patients with calcium 
and active vitamin D preparations has resulted in adverse effects such as hypercalciuria, nephrocalcinosis, 
and nephrolithiasis (7, 10). Although calcilytic compounds represented targeted therapies for patients with 
CaSR mutations causing symptomatic forms of  ADH1 (12, 13), it was unclear if  these CaSR allosteric 
modulators may rectify abnormalities of  the downstream Gα11 protein, and thus have potential benefit for 
ADH2 patients. Recent in vitro studies have revealed that low doses (10 nM to 30 nM concentrations) of  the 
NPS-2143 calcilytic compound can successfully correct the gain of  function associated with ADH2-causing 
Gα11 mutations (11). Consistent with these findings, a similar dose of  NPS-2143 also normalized the Ca
2+
i 
and MAPK responses of  the Ile62Val Gα11 mutant (Figures 3 and 4). Moreover, we have shown that admin-
istration of  a single NPS-2143 dose induced a rapid and marked rise in PTH concentrations in Dsk7/+ and 
Dsk7/Dsk7 mice, and rectified or improved their hypocalcemic phenotypes, respectively (Figure 5); these 
data suggest that Dsk7/Dsk7 mice will likely require a higher dose of  NPS-2143 to correct their hypocal-
caemia. These results suggest that calcilytics such as NPS-2143 will likely be of  benefit for ADH2 patients, 
who also harbor heterozygous GNA11 mutations (2, 7, 8, 10). Oral administration of  NPS-2143 was well 
tolerated, and the acute rise in plasma calcium after dose did not affect the health or condition of  the mice, 
nor did it influence biochemical parameters such as electrolytes or renal function. However, an increase in 
plasma phosphate was noted in WT mice following treatment with NPS-2143, and this finding has also 
been reported in Nuf mice, which became hyperphosphatemic and had increases in urea and creatinine 
following a single i.p. injection of  NPS-2143 (13). However, the rise in phosphate observed in the pres-
ent study was not associated with alterations in renal function, and the cause of  the hyperphosphatemia 
remains to be elucidated. Longer-term studies involving repetitive dosing are required to confirm the effi-
cacy and safety of  calcilytics for improving circulating calcium concentrations in the setting of  ADH2. Of  
note, blood samples obtained from mice under isoflurane terminal anesthesia (Table 1) showed significant 
elevations in plasma concentrations of  phosphate and PTH compared with samples obtained using topical 
local anesthesia (Supplemental Figure 5). General anesthetics, which include inhalation agents such as 
isoflurane, have been reported in laboratory animal studies to significantly alter plasma concentrations of  
phosphate and PTH (38, 39). Our findings further highlight the effects of  anesthetic agents on these com-
monly measured biochemical parameters.
In conclusion, we have established that Dsk7 mice, which harbor a germline gain-of-function Gα11 muta-
tion, represent an in vivo model for the human disorder of  ADH2. We have also utilized this model to demon-
strate that calcilytic compounds have the potential to treat the hypocalcemia associated with this disorder.
Methods
Animals. Dsk7 mice were rederived on a C3H strain background (C3H.C3HeB/FeJ-Gna11Mhdadsk7/IegH) 
by in vitro fertilization using sperm obtained from the European Mutant Mouse Archive (EMMA). All 
study mice were aged between 12–16 weeks and housed in a controlled environment at the MRC Harwell 
Institute in accordance with UK Home Office and MRC welfare guidance. Mice had free access to water 
and were fed ad libitum on a commercial diet (RM3, Special Diet Services) that contained 1.15% calcium, 
0.58% phosphate, and 4089 IU/kg of  vitamin D.
Compounds. NPS-2143 hydrochloride (also known as 2-Chloro-6-[(2R)-3-[[1,1-dimethyl-2-(2-naphthale-
nyl)ethyl]amino]-2-hydroxypropoxy]-benzonitrile hydrochloride) was obtained from Sigma-Aldrich (cata-
log SML0362) and dissolved in a 20% aqueous solution of  2-hydroxypropyl-β-cyclodextrin (Sigma-Aldrich, 
catalog H107) prior to use in in vitro and in vivo studies.
DNA sequence analysis. Genomic DNA was extracted from auricular biopsies, as described (40), and 
gene-specific primers were used to perform PCR amplification and DNA sequence analysis of  Gna11 exon 
2, as reported (2). The germline Gna11 mutation was confirmed by FokI restriction endonuclease analysis 
(New England Biolabs), as previously described (20).
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Protein sequence alignment and 3-dimensional modeling. Protein sequences of  Gα11 were aligned using 
ClustalOmega (http://www.ebi.ac.uk/Tools/msa/clustalo/) (41). PyMOL Molecular Graphics System 
(Version 1.2r3pre, Schrödinger, PyMOL) (16) was used to model the effects of  the Gα11 Ile62Val mutation. 
Gα11 3-dimensional (3-D) modeling was undertaken using the reported 3-D structure of  Gαq in complex 
with the small molecule inhibitor YM-254890 (Protein Data Bank accession no. 3AH8) (22) and also using 
the reported structure of  the Gαi protein (Protein Data Bank accession no. 1GDD) (23).
Cell culture and protein expression. Functional studies were undertaken using a human GNA11 construct 
(2), as the human and mouse Gα11 proteins share an overall amino acid identity of  98% and are 100% 
identical in the region surrounding the mutated site. The Val62 mutation was introduced by site-directed 
mutagenesis (QuikChange Lightning, Agilent Technologies) into a pBI-CMV2-GNA11 expression con-
struct, as described (2). WT and mutant pBI-CMV2-GNA11 constructs were transiently transfected into 
HEK293 cells that stably express the full-length human CASR cDNA (HEK-CaSR), as described (2, 42, 
43). HEK293 cells were used because suitable parathyroid and renal tubular cells are not available, and 
HEK293 cells have been established as a model for the functional expression of  Gα11 proteins (2, 43, 
44). HEK-CaSR cells were cultured in high-glucose DMEM (Invitrogen) supplemented with 10% FBS 
and 1% geneticin at 37°C, 5% CO2 (2). Successful transfection was confirmed by visualizing GFP fluo-
rescence using an Eclipse E400 fluorescence microscope with an epifluorescence filter, and images were 
captured using a DXM1200C digital camera and NIS Elements software (Nikon) (2, 44). The expression 
of  Gα11 and CaSR proteins was confirmed by Western blot analyses using Gα11 (D-6, sc-390382, San-
ta Cruz Biotechnologies Inc.), anti-GFP (B-2, sc-9996, Santa Cruz Biotechnologies Inc.), anti-calnexin 
(AB2301, Millipore), anti-GAPDH (AM4300, Ambion), or anti-CaSR (5C10, ADD, ab19347, Abcam) 
antibodies. The Western blots were visualized using an Immuno-Star Western C kit (Bio-Rad) on a Bio-
Rad Chemidoc XRS+ system (2, 42). Densitometric analysis was performed using Image J analysis soft-
ware (Version 1.46; rsb.info.nih.gov/ij/), and statistical analysis was performed using 2-way ANOVA, as 
previously described (45).
Measurement of  Ca2+i responses. The effect of  the mutant Gα11 protein on the Ca
2+
i responses of  CaSR-ex-
pressing cells was assessed by a flow cytometry–based assay, as reported (2, 43, 44). Briefly, 48 hours after 
transfection, the cells were harvested, washed in calcium- and magnesium-free HBSS (Invitrogen), and 
loaded with 1 μg/ml indo-1-acetoxymethylester (Indo-1-AM; Molecular Probes) for 1 hour at 37°C (2, 10, 
11, 42). After the removal of  free dye, the cells were resuspended in calcium- and magnesium-free HBSS 
and maintained at 37°C. Transfected HEK-CaSR cells were incubated with either a 20% aqueous solution 
of  2-hydoxypropyl-β-cyclodextrin (vehicle) or negative allosteric modulator NPS-2143 at concentrations of  
20 nM and 40 nM for 1 hour, as previously described (11).
Transfected cells in suspension were then stimulated by sequentially adding calcium to increase the 
[Ca2+]o in a stepwise manner from 0–15 mM and then analyzed on a MoFlo modular flow cytometer 
(Beckman Coulter) by simultaneous measurement of  GFP expression (at 525 nm), Ca2+i-bound Indo-1AM 
(at 410 nm), and free Indo-1AM (at 485nm), using a JDSU Xcyte UV laser (Coherent Radiation) on each 
cell at each [Ca2+]o, as described (2, 42, 43). Cytomation Summit software was used to determine the peak 
mean fluorescence ratio of  the transient response after each individual stimulus expressed as a normalized 
response (2, 42, 43). Concentration-response curves were generated using a 4-parameter nonlinear regres-
sion curve-fit model (GraphPad Prism) to calculate the EC50 and Hill coefficient values (2, 10, 11, 42, 44). 
The maximal signaling response was measured as a fold-change of  the peak transient Ca2+i response to the 
basal Ca2+i response. The maximal signaling response of  mutant-expressing cells was expressed as a per-
centage of  the WT maximal signaling response (11).
Measurement of  ERK1/2 phosphorylation. HEK-CaSR cells were seeded in 48-well plates and transfected 
with 200 ng WT or mutant Gα11 proteins 24 hours prior to conducting the assays. Transfected cells were 
incubated in serum-free media 12 hours prior to treatment of  cells with 0–10 mM CaCl2. Cells were lysed 
in Surefire lysis buffer, and AlphaScreen Surefire ERK assays measuring phosphorylated and total proteins 
were performed as previously described (11). For studies with negative allosteric modulators, cells were 
incubated with either a 20% aqueous solution of  2-hydoxypropyl-β-cyclodextrin (vehicle) or NPS-2143 for 
4 hours prior to being stimulated with 10 mM CaCl 2 . The fluorescence signal in both assays was measured 
using the PheraStar FS microplate reader (BMG Labtech) (11, 45).
Measurement of  serum response element (SRE) luciferase reporter activity. HEK-CaSR cells were seeded in 
48-well plates and transiently transfected with 100 ng/ml Gα11 WT or mutant proteins, 100 ng pGL4-SRE 
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luciferase reporter construct, and 10 ng/ml pRL control vector for 48 hours (Promega). Cells were incu-
bated in serum-free media for 12 hours, followed by treatment of  cells for 4 hours with 0–10 mM CaCl 2 . 
Cells were lysed and assays performed using Dual-Glo luciferase (Promega) on a Veritas Luminometer 
(Promega), as previously described (25, 45).
Plasma biochemistry and hormone analysis. Blood samples were collected from the lateral tail vein of  
study mice following application of  topical local anesthesia, as reported (40), or collected from the ret-
ro-orbital vein under isoflurane terminal anesthesia. Lateral tail vein sampling provides small volumes 
of  blood that are adequate for analysis of  plasma calcium, albumin, phosphate, PTH, urea, and creati-
nine. However, retro-orbital vein sampling under terminal general anaesthesia is required to obtain larger 
blood volumes that permit analysis of  a wider range of  biochemical parameters. Plasma was separated by 
centrifugation at 5,000 g for 10 minutes at 8°C and analyzed for sodium, potassium, total calcium, mag-
nesium, phosphate, urea, creatinine, albumin, and alkaline phosphatase on an Beckman Coulter AU680 
analyzer, as described previously (13). Plasma calcium was adjusted for variations in albumin concentra-
tions using the formula: (plasma calcium (mmol/l) – [(plasma albumin (g/l) – 30) × 0.02], as reported 
(40). Hormones were measured as follows: PTH using a 2-site ELISA kit (Immunotopics); intact FGF-23 
using a 2-site ELISA kit (Kainos Laboratoties); and 1,25-dihydroxyvitamin D measured by a 2-step pro-
cess involving purification by immunoextraction and quantification by enzyme immunoassay (Immunodi-
agnostic Systems), as described (46).
Metabolic cages and urine biochemistry analysis. Mice were individually housed in metabolic cages 
(Techniplast) and fed ad libitum on water and powdered chow. Mice were allowed to acclimatize to 
their environment over a 72-hour period, as described (47), prior to collection of  24-hour urine samples. 
Urine was analyzed for sodium, potassium, creatinine, phosphate, and calcium on a Beckman Coulter 
AU680 analyzer, as reported (13). The fractional excretion of  sodium, potassium, and calcium were 
calculated using the formula Ux/Px × PCr/UCr, where Ux is the urinary concentration of  the filtered 
substance (substance x) in mmol/l, Px is the plasma concentration of  substance x in mmol/l, UCr is 
the urinary concentration of  creatinine in mmol/l, and PCr is the plasma concentration of  creatinine 
in mmol/l (13). The ratio of  TmP to GFR (TmP/GFR) was calculated using the following formula: 
PPi × (1 – [UPi/PPi × PCr/UCr ]), where PPi is the plasma concentration of  phosphate and UPi is the urine 
concentration of  phosphate.
Skeletal imaging. BMD was assessed by whole body DXA scanning, which was performed on mice 
anesthetized by inhaled isoflurane and using a Lunar Piximus densitometer (GE Medical Systems), as 
reported (46). DXA images were analyzed using Piximus software, as reported (46). Trabecular bone vol-
ume and structure were assessed by μCT analysis of  the proximal tibia using a SkyScan 1174 scanner 
(SkyScan), with X-ray settings 50 kV, 800 μA, 12.6 μm isometric voxel resolution, and 0.7 degree rotation 
step. The tibial trabecular region, located 1.5 mm distally from the growth plate, was selected for analysis, 
and a volume of  interest was delineated by drawing within the cortex of  the trabecular region. A threshold 
of  80–255 density units was selected to distinguish mineralized trabecular tissue from surrounding soft tis-
sue of  the marrow cavity. Cross-sectional images were obtained and 3-D reconstruction undertaken using 
Skyscan CT Analyzer software (version 1.9.3.0).
In vivo administration of  NPS-2143. NPS-2143 was administered as a single 100 μmol/kg (~45 mg/kg) 
dose by oral gavage or as a single 30 mg/kg dose by i.p. injection, as described (13), and plasma samples 
were collected by tail vein bleed at either 0, 1, 2, 6, or 24 hours after dose.
Statistics. All in vitro studies involved between 2–12 separate transfection experiments and between 4–8 
technical assays. For the in vitro measurement of  Ca2+i EC50 responses, statistical comparisons were under-
taken using the F-test (2, 11), whereas, Ca2+i maximal signaling responses and Hill coefficients were analyzed 
using the Mann-Whitney U test. Measurements of  ERK phosphorylation and SRE gene luciferase reporter 
activity were analyzed using the Mann-Whitney U test or by 2-way ANOVA with Tukey’s multiple-com-
parisons test. For the in vivo studies, a Kruskal-Wallis test was undertaken for multiple comparisons, and 
any significant differences identified were further assessed using the Dunn’s test for nonparametric pairwise 
multiple comparisons. All analyses were undertaken using GraphPad Prism software, and a value of  P < 
0.05 was considered significant for all analyses.
Study approval. Animal studies were approved by the MRC Harwell Institute Ethical Review Commit-
tee and were licensed under the Animal (Scientific Procedures) Act 1986, issued by the UK Government 
Home Office Department (PPL30/3271).
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